<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291980</url>
  </required_header>
  <id_info>
    <org_study_id>HN018/HBV-004 (105754)</org_study_id>
    <nct_id>NCT00291980</nct_id>
    <nct_alias>NCT00739804</nct_alias>
  </id_info>
  <brief_title>A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.</brief_title>
  <official_title>A Phase III, Multicentric, Multinational, Controlled, Randomised, Open Study Comparing the Immunogenicity, Reactogenicity and Safety of Henogen's New Adjuvanted Hepatitis B Vaccine, HB-AS02V, to That of Aventis Pasteur MSD's Hepatitis B Vaccine, HBVAXPRO® , Administered as a Booster Dose in Pre-Dialysis, Peritoneal Dialysis and Haemodialysis Subjects (³ 15 Years of Age) Who Previously Responded to Hepatitis B Primary Vaccination But Have Lost Antibody.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The immune response of uraemic patients to hepatitis B vaccination is impaired compared to
      healthy subjects. After vaccination, anti-HBs peak antibody concentrations are reduced. As
      the persistence of anti-HBs is closely related to the initial anti-HBs peak, a more
      immunogenic vaccine, allowing higher antibody concentrations, would be a benefit for this
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive either Henogen's adjuvanted hepatitis B vaccine or Aventis
      Pasteur's hepatitis B vaccine. The study involves a total of 3 visits and blood samples will
      taken at each of these visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs antibody geometric mean concentrations.</measure>
    <time_frame>Month 0 and Month 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates for all subjects</measure>
    <time_frame>Months 0, 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rates for all subjects</measure>
    <time_frame>Month 0 and at Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with anti-HBs antibody concentrations superior or equal to 100 mIU/ml for all subjects</measure>
    <time_frame>Month 0 and at Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of anti-HBs antibodies for all subjects and for seropositive subjects</measure>
    <time_frame>Month 0 and Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and intensity of solicited local signs and symptoms, relationship to vaccination of solicited general signs and symptoms during the 4-day follow-up after vaccination</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of unsolicited local and general signs and symptoms during the 31-day (Day 0 to Day 30) follow-up period after vaccination</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of all serious adverse events up to Month 1</measure>
    <time_frame>Month 0 to 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HB-AS02V vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBVAXPRO vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-AS02V vaccine</intervention_name>
    <description>HB-AS02V (20µg HBsAg) will be administered at Month 0</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBVAXPRO vaccine</intervention_name>
    <description>HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects whom the investigator believes that they can and will comply with the
             requirements of the protocol (e.g., completion of the diary cards, return for
             follow-up visits) should be enrolled in the study.

          -  A male or female subject 15 years of age or older at the time of the study entry.

          -  Written informed consent obtained from the subject/ subject's parents or guardians.

          -  Pre-dialysis patients, peritoneal dialysis patients and patients on haemodialysis.
             Pre-dialysis patients is defined as a subject with a documented creatinine clearance
             of les or equal to 30 ml/min.

          -  Seronegative for anti-HBc antibodies and for HBsAg at screening.

          -  Documented previous hepatitis B vaccination with one full primary course of licensed
             vaccine (the cumulative dose for primary vaccination is at least 160 mg of hepatitis B
             vaccine) with or without subsequent boosters. The last dose should have been
             administered at least three months before the planned dose of study vaccine in this
             study.

          -  Documented response to previous hepatitis B vaccination (i.e. anti-HBs antibody
             concentrations ³ 10 mIU/ml after primary vaccination or after booster/s with licensed
             vaccine), but for whom there is a loss of anti-HBs antibody concentrations below 10
             mIU/ml at the time of inclusion into the study. Patients who have antibody
             concentrations below 50 mIU/ml at the time of inclusion will also be recruited
             provided that this antibody concentration is less than half of the highest documented
             antibody response achieved after primary vaccination or booster/s. The interval
             between the blood sample corresponding to the documented response and the hepatitis B
             vaccine dose received prior to this blood sample should be at least 25 days

          -  If the subject is female, she must be of non-childbearing potential, i.e., either
             surgically sterilized or one year post-menopausal; or, if of childbearing potential,
             she must be abstinent or have used medically-approved contraceptive precautions for 30
             days prior to vaccination, have a negative pregnancy test and must agree to continue
             such precautions for two months after completion of the vaccination series.

        Exclusion Criteria:

          -  Subjects who have participated in the HN014/HBV-001 or HN017/HBV-003 study

          -  Use of any investigational or non-registered drug or vaccine within 30 days preceding
             the study vaccine administration, or planned use during the study period.

          -  Use of any registered vaccine within 7 days preceding the study vaccine
             administration.

          -  History of hepatitis B infection.

          -  Known exposure to hepatitis B virus within six months.

          -  Use of immunoglobulins within six months preceding the first study vaccination.

          -  Immunosuppression caused by the administration of parenteral steroids or chemotherapy
             (oral steroids are allowed).

          -  Any confirmed or suspected human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Acute disease at the time of enrolment. (Acute disease is defined as the presence of a
             moderate or severe illness with or without fever. All vaccines can be administered to
             persons with a minor illness such as diarrhoea, mild upper respiratory infection with
             or without low-grade febrile illness, i.e., oral/ axillary temperature &lt; 37.5°C (or 37
             °C in Czech Republic).

          -  Oral/axillary temperature equal or superior to 37.5 °C (or 37 °C in Czech Republic).

          -  Pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Tielemans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ULB Hôpital Erasme Département de Néphrologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>O.L.Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS La Madeleine ATH</name>
      <address>
        <city>ATH</city>
        <zip>7800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS Clinique Louis Caty Baudour</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann (site V Horta) Service de néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme Département de Néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital civil de</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ AntwerpenDienst nefrologie</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg Leuven Nierziekten</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Andre VESALE</name>
      <address>
        <city>Montigny le tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS TournayService de néphrologie</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Gerontology and MetabolismDepartment of NephrologyUniversity HospitalSokolska</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>581500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital JihlavaVrchlického</name>
      <address>
        <city>Jihlava</city>
        <zip>59586 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of NephrologyIII. Clinic of Internal DiseasesUniversity Hospital I.P.Pavlova</name>
      <address>
        <city>Olomouc</city>
        <zip>6775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infection Diseases and AIDS Treatment ClinicUniversity Hospital with Outpatient Clinic</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>1790708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care - DS, s.r.o.: PardubiceDialysis Unit Kyjevska</name>
      <address>
        <city>Pardubice</city>
        <zip>44532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care - DS Prague 4</name>
      <address>
        <city>Prague</city>
        <zip>142 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine StrahovSermirska 5</name>
      <address>
        <city>Prague</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care - DS, s.r.o.: SokolovDialysis Unit Slovenska</name>
      <address>
        <city>Sokolov</city>
        <zip>1863356 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Science CenterI. Medical Clinic for Internal Diseases Nephrology Department</name>
      <address>
        <city>Debrecen</city>
        <zip>.H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc County HospitalFresenius Dialysis Center Baktai</name>
      <address>
        <city>Eger</city>
        <zip>H-3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos HospitalFresenius Dialysis Center</name>
      <address>
        <city>Esztergom</city>
        <zip>H-2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Teaching Hospital Vasvári</name>
      <address>
        <city>Győr</city>
        <zip>H-9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hatvan Hospital Health Care ProviderFresenius Dialysis Center Hatvan .</name>
      <address>
        <city>Hatvan</city>
        <zip>H-3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas and Szombathely County Markusovszky Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>August 27, 2008</last_update_submitted>
  <last_update_submitted_qc>August 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sophie Houard CSO</name_title>
    <organization>Henogen</organization>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Pre-dialysis</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Prophylaxis hepatitis B infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

